Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor

被引：0
|
作者：
Shapiro, Geoffrey I. [1 ]
Edelman, Gerald [2 ]
Calvo, Emiliano [3 ]
Aggarwal, Sanjay K. [4 ]
Laird, A. Douglas [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mary Crowley Canc Res Ctrs, Dallas, TX USA
[3] Vall Hebron Univ Hosp, Barcelona, Spain
[4] Exelixis Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3594S / 3594S
页数：1
相关论文
共 50 条
  • [1] Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147
    Foster, Paul G.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3592S - 3592S
  • [2] Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor
    Martinez Gonzalez, Sonia
    Isabel Hernandez, Ana
    Varela, Carmen
    Rodriguez-Aristegui, Sonsoles
    Lorenzo, Milagros
    Rodriguez, Antonio
    Rivero, Virginia
    Ignacio Martin, Jose
    Gustav Saluste, Carl
    Ramos-Lima, Francisco
    Cendon, Elena
    Cebrian, David
    Aguirre, Enara
    Gomez-Casero, Elena
    Albarran, Maribel
    Alfonso, Patricia
    Garcia-Serelde, Beatriz
    Oyarzabal, Julen
    Rabal, Obdulia
    Mulero, Francisca
    Gonzalez-Granda, Teresa
    Link, Wolfgang
    Fominaya, Jesus
    Barbacid, Mariano
    Bischoff, James R.
    Pizcueta, Pilar
    Pastor, Joaquin
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (10) : 3460 - 3466
  • [3] Targeting the PI3K signaling pathway in cancer
    Wong, Kwok-Kin
    Engelman, Jeffrey A.
    Cantley, Lewis C.
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2010, 20 (01) : 87 - 90
  • [4] Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
    Shapiro, G.
    Kwak, E.
    Baselga, J.
    Rodon, J.
    Scheffold, C.
    Laird, A. D.
    Bedell, C.
    Edelman, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Targeting the PI3K signaling pathway in cancer therapy
    Bartholomeusz, Chandra
    Gonzalez-Angulo, Ana Maria
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) : 121 - 130
  • [6] Targeting PI3K/AKT signaling pathway in obesity
    Savova, Martina S.
    Mihaylova, Liliya, V
    Tews, Daniel
    Wabitsch, Martin
    Georgiev, Milen I.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 159
  • [7] Targeting the PI3K pathway in cancer
    Workman, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S80 - S80
  • [8] Targeting the PI3K pathway in cancer
    Mills, GB
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S4 - S4
  • [9] Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases
    Erra, Montse
    Taltavull, Joan
    Greco, Angelique
    Javier Bernal, Francisco
    Francisco Caturla, Juan
    Gracia, Jordi
    Dominguez, Maria
    Sabate, Mar
    Paris, Stephane
    Soria, Salome
    Hernandez, Begona
    Armengol, Clara
    Cabedo, Judit
    Bravo, Monica
    Calama, Elena
    Miralpeix, Montserrat
    Lehner, Martin D.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 118 - 123
  • [10] Targeting PI3K
    Cantley, L.
    Lewis, C. Cantley
    [J]. CANCER RESEARCH, 2012, 72
12345